Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Francesc Castro-Giner is active.

Publication


Featured researches published by Francesc Castro-Giner.


European Respiratory Journal | 2008

Air pollution, oxidative stress and dietary supplementation: a review

Isabelle Romieu; Francesc Castro-Giner; Nino Künzli; Jordi Sunyer

The aim of the present review was to provide an up-to-date overview of the biological and epidemiological evidence of the role of oxidative stress as a major underlying feature of the toxic effect of air pollutants, and the potential role of dietary supplementation in enhancing antioxidant defences. A bibliographic search was conducted through PubMed. The keywords used in the search were “air pollutant”, “oxidative stress”, “inflammation”, “antioxidant polyunsaturated fatty acids” and “genetics”. In addition, the authors also searched for biomarkers of oxidative stress and nutrients. The review presents the most recent data on: the biological and epidemiological evidence of the oxidative stress response to air pollutants; the role of dietary supplementation as a modulator of these effects; and factors of inter-individual variation in human response. The methodology for further epidemiological studies will be discussed in order to improve the current understanding on how nutritional factors may act. There is substantial evidence that air pollution exposure results in increased oxidative stress and that dietary supplementation may play a modulating role on the acute effect of air pollutants. Further epidemiological studies should address the impact of supplementation strategies in the prevention of air-pollution-related long-term effects in areas where people are destined to be exposed for the distant future.


Nature Genetics | 2013

Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy

Cristina Balbás-Martínez; Ana Sagrera; Enrique Carrillo-de-Santa-Pau; Julie Earl; Mirari Marquez; Miguel Vazquez; Eleonora Lapi; Francesc Castro-Giner; Sergi Beltran; Mònica Bayés; Alfredo Carrato; Juan C. Cigudosa; Orlando Domínguez; Marta Gut; Jesús Herranz; Nuria Juanpere; Manolis Kogevinas; Xavier Langa; Elena Lopez-Knowles; José A. Lorente; Josep Lloreta; David G. Pisano; Laia Richart; Daniel Rico; Rocío Salgado; Adonina Tardón; Stephen J. Chanock; Simon Heath; Alfonso Valencia; Ana Losada

Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological and genetic levels. Tumor invasiveness (T) and grade (G) are the main factors associated with outcome and determine patient management. A discovery exome sequencing screen (n = 17), followed by a prevalence screen (n = 60), identified new genes mutated in this tumor coding for proteins involved in chromatin modification (MLL2, ASXL2 and BPTF), cell division (STAG2, SMC1A and SMC1B) and DNA repair (ATM, ERCC2 and FANCA). STAG2, a subunit of cohesin, was significantly and commonly mutated or lost in UBC, mainly in tumors of low stage or grade, and its loss was associated with improved outcome. Loss of expression was often observed in chromosomally stable tumors, and STAG2 knockdown in bladder cancer cells did not increase aneuploidy. STAG2 reintroduction in non-expressing cells led to reduced colony formation. Our findings indicate that STAG2 is a new UBC tumor suppressor acting through mechanisms that are different from its role in preventing aneuploidy.


Cell | 2013

A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection.

Jorge Zeron-Medina; Xuting Wang; Emmanouela Repapi; Michelle R. Campbell; Dan Su; Francesc Castro-Giner; Benjamin Davies; Elisabeth F.P. Peterse; Natalia Sacilotto; Graeme J. Walker; Tamara Terzian; Ian Tomlinson; Neil F. Box; Nicolai Meinshausen; Sarah De Val; Douglas A. Bell; Gareth L. Bond

The ability of p53 to regulate transcription is crucial for tumor suppression and implies that inherited polymorphisms in functional p53-binding sites could influence cancer. Here, we identify a polymorphic p53 responsive element and demonstrate its influence on cancer risk using genome-wide data sets of cancer susceptibility loci, genetic variation, p53 occupancy, and p53-binding sites. We uncover a single-nucleotide polymorphism (SNP) in a functional p53-binding site and establish its influence on the ability of p53 to bind to and regulate transcription of the KITLG gene. The SNP resides in KITLG and associates with one of the largest risks identified among cancer genome-wide association studies. We establish that the SNP has undergone positive selection throughout evolution, signifying a selective benefit, but go on to show that similar SNPs are rare in the genome due to negative selection, indicating that polymorphisms in p53-binding sites are primarily detrimental to humans.


American Journal of Human Genetics | 2012

Spinal Muscular Atrophy Associated with Progressive Myoclonic Epilepsy Is Caused by Mutations in ASAH1

Jie Zhou; Marcel Tawk; Francesco Danilo Tiziano; Julien Veillet; Mònica Bayés; Flora Nolent; Virginie Garcia; Serenella Servidei; Enrico Bertini; Francesc Castro-Giner; Yavuz Renda; Stéphane Carpentier; Nathalie Andrieu-Abadie; Ivo Gut; Thierry Levade; Haluk Topaloglu; Judith Melki

Spinal muscular atrophy (SMA) is a clinically and genetically heterogeneous disease characterized by the degeneration of lower motor neurons. The most frequent form is linked to mutations in SMN1. Childhood SMA associated with progressive myoclonic epilepsy (SMA-PME) has been reported as a rare autosomal-recessive condition unlinked to mutations in SMN1. Through linkage analysis, homozygosity mapping, and exome sequencing in three unrelated SMA-PME-affected families, we identified a homozygous missense mutation (c.125C>T [p.Thr42Met]) in exon 2 of ASAH1 in the affected children of two families and the same mutation associated with a deletion of the whole gene in the third family. Expression studies of the c.125C>T mutant cDNA in Farber fibroblasts showed that acid-ceramidase activity was only 32% of that generated by normal cDNA. This reduced activity was able to normalize the ceramide level in Farber cells, raising the question of the pathogenic mechanism underlying the CNS involvement in deficient cells. Morpholino knockdown of the ASAH1 ortholog in zebrafish led to a marked loss of motor-neuron axonal branching, a loss that is associated with increased apoptosis in the spinal cord. Our results reveal a wide phenotypic spectrum associated with ASAH1 mutations. An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.


Nature Communications | 2015

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

Michal Kovac; Claudia Blattmann; Sebastian Ribi; Jan Smida; Nikola S. Mueller; Florian Engert; Francesc Castro-Giner; Joachim Weischenfeldt; Monika Kováčová; Andreas H. Krieg; Dimosthenis Andreou; Per-Ulf Tunn; Hans Roland Dürr; Hans Rechl; Klaus-Dieter Schaser; I. Melcher; Stefan Burdach; Andreas E. Kulozik; Katja Specht; Karl Heinimann; Simone Fulda; Stefan S. Bielack; Gernot Jundt; Ian Tomlinson; Jan O. Korbel; Michaela Nathrath; Daniel Baumhoer

Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has historically complicated driver gene discovery. Here we sequence exomes of 31 tumours and decipher their evolutionary landscape by inferring clonality of the individual mutation events. Exome findings are interpreted in the context of mutation and SNP array data from a replication set of 92 tumours. We identify 14 genes as the main drivers, of which some were formerly unknown in the context of osteosarcoma. None of the drivers is clearly responsible for the majority of tumours and even TP53 mutations are frequently mapped into subclones. However, >80% of osteosarcomas exhibit a specific combination of single-base substitutions, LOH, or large-scale genome instability signatures characteristic of BRCA1/2-deficient tumours. Our findings imply that multiple oncogenic pathways drive chromosomal instability during osteosarcoma evolution and result in the acquisition of BRCA-like traits, which could be therapeutically exploited.


Nature Communications | 2015

Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution

Michal Kovac; Carolina Navas; Stuart Horswell; M. Salm; Chiara Bardella; Andrew Rowan; Mark Stares; Francesc Castro-Giner; Rosalie Fisher; E. C de Bruin; Monika Kováčová; Maggie Gorman; Seiko Makino; J Williams; Emma Jaeger; Angela Jones; Km Howarth; James Larkin; L. M. Pickering; Martin Gore; David L. Nicol; Steven Hazell; Gordon Stamp; Tim O'Brien; Ben Challacombe; Nik Matthews; Benjamin Phillimore; Sharmin Begum; Adam Rabinowitz; Ignacio Varela

Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behaviour. Here we sequence the genomes or exomes of 31 pRCCs, and in four tumours, multi-region sequencing is undertaken. We identify BAP1, SETD2, ARID2 and Nrf2 pathway genes (KEAP1, NHE2L2 and CUL3) as probable drivers, together with at least eight other possible drivers. However, only ~10% of tumours harbour detectable pathogenic changes in any one driver gene, and where present, the mutations are often predicted to be present within cancer sub-clones. We specifically detect parallel evolution of multiple SETD2 mutations within different sub-regions of the same tumour. By contrast, large copy number gains of chromosomes 7, 12, 16 and 17 are usually early, monoclonal changes in pRCC evolution. The predominance of large copy number variants as the major drivers for pRCC highlights an unusual mode of tumorigenesis that may challenge precision medicine approaches.


Human Immunology | 2009

STAT4 gene polymorphism is associated with psoriasis in the genetically homogeneous population of Crete, Greece.

Maria Zervou; George N. Goulielmos; Francesc Castro-Giner; Androniki D. Tosca; Sabine Krueger-Krasagakis

Recent genome-wide association studies (GWAS) of many complex diseases have successfully identified novel susceptibility loci, with many of them being associated with more than one condition. Taking into consideration that different autoimmune diseases may share some common pathogenetic pathways, we hypothesized that STAT4, a susceptibility gene found to be associated with increased risk for systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, Sjögrens syndrome, Wegeners granulomatosis, Crohns disease, and ulcerative colitis may also have a role in psoriasis. Psoriasis is an autoimmune, chronic inflammatory skin disease. Here we performed a case-control study in the population of island of Crete and demonstrated for the first time the association of a STAT4 single nucleotide polymorphism (SNP) with susceptibility to psoriasis, thus suggesting a putative key role of STAT4 in multiple autoimmune diseases. We found that mutated allele T of the STAT4 rs7574865 SNP, which previously was implicated in the predisposition to many autoimmune diseases, were more common in individuals with psoriasis than in controls (p = 0.045, odds ratio = 1.42, 95% confidence interval 1.01-2.00), thus concluding that the polymorphism examined is associated with the development of psoriasis in our population.


BMC Medical Genetics | 2009

A pooling-based genome-wide analysis identifies new potential candidate genes for atopy in the European Community Respiratory Health Survey (ECRHS)

Francesc Castro-Giner; Mariona Bustamante; Juan R. González; Manolis Kogevinas; Deborah Jarvis; Joachim Heinrich; J. M. Anto; Matthias Wjst; Xavier Estivill; Rafael de Cid

BackgroundAsthma and atopy are complex phenotypes with shared genetic component. In this study we attempt to identify genes related to these traits performing a two-stage DNA pooling genome-wide analysis in order to reduce costs. First, we assessed all markers in a subset of subjects using DNA pooling, and in a second stage we evaluated the most promising markers at an individual level.MethodsFor the genome-wide analysis, we constructed DNA pools from 75 subjects with atopy and asthma, 75 subjects with atopy and without asthma and 75 control subjects without atopy or asthma. In a second stage, the most promising regions surrounding significant markers after correction for false discovery rate were replicated with individual genotyping of samples included in the pools and an additional set of 429 atopic subjects and 222 controls from the same study centres.ResultsHomo sapiens protein kinase-like protein SgK493 (SGK493) was found to be associated with atopy. To lesser extent mitogen-activated protein kinase 5 (MAP3K5), collagen type XVIII alpha 1 (COL18A1) and collagen type XXIX alpha 1 (COL29A1) were also found to be associated with atopy. Functional evidences points out a role for MAP3K5, COL18A1 and COL29A1 but the function of SGK493 is unknown.ConclusionIn this analysis we have identified new candidate regions related to atopy and suggest SGK493 as an atopy locus, although these results need further replication.


European Journal of Human Genetics | 2010

A screening methodology based on Random Forests to improve the detection of gene-gene interactions

Lizzy De Lobel; Pierre Geurts; Guy Baele; Francesc Castro-Giner; Manolis Kogevinas; Kristel Van Steen

The search for susceptibility loci in gene–gene interactions imposes a methodological and computational challenge for statisticians because of the large dimensionality inherent to the modelling of gene–gene interactions or epistasis. In an era in which genome-wide scans have become relatively common, new powerful methods are required to handle the huge amount of feasible gene–gene interactions and to weed out false positives and negatives from these results. One solution to the dimensionality problem is to reduce data by preliminary screening of markers to select the best candidates for further analysis. Ideally, this screening step is statistically independent of the testing phase. Initially developed for small numbers of markers, the Multifactor Dimensionality Reduction (MDR) method is a nonparametric, model-free data reduction technique to associate sets of markers with optimal predictive properties to disease. In this study, we examine the power of MDR in larger data sets and compare it with other approaches that are able to identify gene–gene interactions. Under various interaction models (purely and not purely epistatic), we use a Random Forest (RF)-based prescreening method, before executing MDR, to improve its performance. We find that the power of MDR increases when noisy SNPs are first removed, by creating a collection of candidate markers with RFs. We validate our technique by extensive simulation studies and by application to asthma data from the European Committee of Respiratory Health Study II.


Nature Reviews Cancer | 2016

The importance of p53 pathway genetics in inherited and somatic cancer genomes

Giovanni Stracquadanio; Xuting Wang; Marsha D. Wallace; Anna M. Grawenda; Ping Zhang; Juliet Hewitt; Jorge Zeron-Medina; Francesc Castro-Giner; Ian Tomlinson; Colin R. Goding; Kamil J. Cygan; William G. Fairbrother; Laurent F. Thomas; Pål Sætrom; Federica Gemignani; Stefano Landi; Benjamin Schuster-Böckler; Douglas A. Bell; Gareth L. Bond

Decades of research have shown that mutations in the p53 stress response pathway affect the incidence of diverse cancers more than mutations in other pathways. However, most evidence is limited to somatic mutations and rare inherited mutations. Using newly abundant genomic data, we demonstrate that commonly inherited genetic variants in the p53 pathway also affect the incidence of a broad range of cancers more than variants in other pathways. The cancer-associated single nucleotide polymorphisms (SNPs) of the p53 pathway have strikingly similar genetic characteristics to well-studied p53 pathway cancer-causing somatic mutations. Our results enable insights into p53-mediated tumour suppression in humans and into p53 pathway-based cancer surveillance and treatment strategies.

Collaboration


Dive into the Francesc Castro-Giner's collaboration.

Top Co-Authors

Avatar

Deborah Jarvis

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ian Tomlinson

University of Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jordi Sunyer

Autonomous University of Barcelona

View shared research outputs
Researchain Logo
Decentralizing Knowledge